Career Highlight
- 30+ years building value in biotech and pharma. Amgen, Genentech, GSK and two clinical-stage biotech’s, leading assets from pre-IND to NDA/BLA, approval and commercial lifecycle management across the US, EU and international markets.
- Regulatory strategy that moves valuation. Experience in taking early assets across development though IPO.
- Fit for purpose scale. Experience from leading regulatory as a one-person self-built function through building and leading a large regional organisation for Amgen.
- Deal and board ready. Experience with regulatory due diligence for licensing, M&A, BD and board advisory roles.
Background Experience
Sarah Popham is Head of Regulatory for SRP-001, a novel non-opioid small molecule.
Most recently she was VP, Head of Regulatory Affairs at Latigo Biotherapeutics (NaV1.8 non-opioid pain) where she led the function from Phase 1 to Phase 3 and through IPO and prior was VP, Head of Regulatory Affairs at AtaiBeckley, setting strategy for drugs, devices and digital therapeutics across a mental health portfolio.
Earlier, she spent several decades in senior regulatory leadership roles working on key regulatory filings across multiple TAs for groundbreaking products such as Lucentis, Rituxan, Avastin, Epogen and Repatha. She holds a B.Sc. in Biomedical Sciences from the University of Bradford, UK.
